Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CardioCell (Wharton's jelly-derived mesenchymal stem cells) for regeneration after acute myocardial infarction
2016-004662-25Phase 2Completed
- Sponsor
- Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Start
- Sep 2017
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in myocardial infarction (MI) comparing CardioCell active therapy with Placebo (2 arms). Primary endpoint: Primary: Infarct size reduction by cardiac MRI. Started Sep 2017; status: completed.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2016-004662-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004662-25.